Every material Form 8-K Moderna filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Moderna reported third-quarter 2024 total revenue of $1.9 billion, up from $1.8 billion a year earlier, and GAAP net income of $13 million, compared with a net loss of $3.6 billion in the prior-year quarter. The company reiterated its 2024 net product sales outlook of $3.0 to $3.5 billion, but cut its full-year research and development expense forecast and raised its capital expenditure estimate, which shareholders will weigh against the lower cash balance.
Q3 2024 total revenue was $1.9 billion, versus $1.8 billion in Q3 2023; GAAP EPS was $0.03 versus a loss of $9.53 per share.
Full-year 2024 R&D expense is now expected at $4.6 to $4.7 billion, down from a previous $4.8 billion.
Full-year 2024 capital expenditures are now expected at about $1.2 billion, up from about $0.9 billion, including about $0.4 billion for the Norwood, MA campus.
Cash, cash equivalents and investments were $9.2 billion at September 30, 2024, down from $10.8 billion at June 30, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Moderna filing is on SEC EDGAR ↗. 8-K briefs of other companies →